AstraZeneca: Transforming How New Medicines Flow to Patients
Below are the available bulk discount rates for each individual item when you purchase a certain amount
Register as a Premium Educator at hbsp.harvard.edu, plan a course, and save your students up to 50% with your academic discount.
Publication Date:
August 16, 2012
Source:
Darden School of Business
David Brennan, CEO of AstraZeneca UK Limited (AZN), was passionate about bringing new medicines to patients. But the industry was transforming to one that featured less patent protection, more competition from generic drugs, stiffer government regulations, and decreased productivity in R&D. The strategy? Build a pipeline with new prescription drugs that were unique enough to provide a differentiated benefit to patients, grow the business globally, streamline the organization and increase efficiency, and build a culture of courage, creativity, and collaboration. Would the firm be able to provide a sustainable and consistent pipeline of new products-at lower cost, likely with fewer people? How might the firm average two new products to market each year? What areas of R&D should the company invest in, and what would the R&D transformation look like?
If you’d like to share this PDF, you can purchase copyright permissions by increasing the quantity.
Copyright © 2020 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.
AstraZeneca: Transforming How New Medicines Flow to Patients
Research & References of AstraZeneca: Transforming How New Medicines Flow to Patients|A&C Accounting And Tax Services
Source